story of the week
Neoadjuvant–Adjuvant vs Adjuvant-Only Pembrolizumab for Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
N. Engl. J. Med 2023 Mar 02;388(9)813-823, SP Patel, M Othus, Y Chen, GP Wright, KJ Yost, JR Hyngstrom, S Hu-Lieskovan, CD Lao, LA Fecher, TG Truong, JL Eisenstein, S Chandra, JA Sosman, KL Kendra, RC Wu, CE Devoe, GB Deutsch, A Hegde, M Khalil, A Mangla, AM Reese, MI Ross, AS Poklepovic, GQ Phan, AA Onitilo, DG Yasar, BC Powers, GC Doolittle, GK In, N Kokot, GT Gibney, MB Atkins, M Shaheen, JA Warneke, A Ikeguchi, JE Najera, B Chmielowski, JG Crompton, JD Floyd, E Hsueh, KA Margolin, WA Chow, KF Grossmann, E Dietrich, VG Prieto, MC Lowe, EI Buchbinder, JM Kirkwood, L Korde, J Moon, E Sharon, VK Sondak, A RibasFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.